The expanding role of nilotinib in chronic myeloid leukemia

Author： Kim Theo Daniel   Coutre Philipp le  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.1, 2011-01, pp. : 97-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia

By Fullmer Amber   Kantarjian Hagop   Cortes Jorge   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3065-3072

Informa Healthcare

Access to resources Recommend Favorite

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

By Shimoni Avichai   Volchek Yulia   Koren-Michowitz Maya   Varda-Bloom Nira   Somech Raz   Shem-Tov Noga   Yerushalmi Ronit   Nagler Arnon  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 863-871

Blackwell Publishing

Access to resources Recommend Favorite

Treatment options for chronic myeloid leukemia

By Tanaka Maria Florencia   Kantarjian Hagop   Cortes Jorge   Ohanian Maro   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 815-828

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for chronic myeloid leukemia

By Cilloni Daniela   Messa Emanuela   Rotolo Antonia   Saglio Giuseppe  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 175-184

Informa Healthcare

Access to resources Recommend Favorite

Emerging Therapies in Chronic Myeloid Leukemia

By  

Current Cancer Drug Targets, Vol. 12, Iss. 5, 2012-05 ,pp. : 458-470

Bentham Science Publishers

Access to resources Recommend Favorite